靶向胃食管癌中ERBB2生物学的复杂性
本文综述胃食管腺癌(GEA)中ERBB2靶向治疗的复杂性。曲妥珠单抗长期是唯一可用药物,但乳腺癌中有效的抗ERBB2药物在GEA多未显示临床获益,主要归因于肿瘤异质性(低表达克隆、ERBB2丢失)。新型检测策略和具有旁观者效应的抗体偶联药物提供新工具;共扩增、MAPK/PI3K通路及细胞周期蛋白改变、NF1突变可被双靶向治疗;免疫机制(ADCC)可能占主导,KEYNOTE-811中期阳性结果支持免疫联合抗ERBB2治疗。
要点
- ERBB2是胃食管腺癌最突出的治疗靶点,但抗ERBB2治疗耐药在GEA中反复出现。
- 耐药主要源于肿瘤异质性:低表达ERBB2克隆存在及ERBB2随时间丢失。
- 新型检测策略和具旁观者效应的抗体偶联药物为对抗异质性提供新工具。
核心结论
- ERBB2靶向治疗在胃食管腺癌中的耐药主要与肿瘤异质性相关,新型检测策略、抗体偶联药物、双靶向治疗及免疫联合抗ERBB2治疗提供新方向。
研究设计与样本
- 综述,总结ERBB2在胃食管腺癌中的生物学复杂性及抗ERBB2治疗耐药机制与对策。
主要发现
- 过去二十年曲妥珠单抗是ERBB2过表达GEA唯一可用治疗。
- 多种在乳腺癌中显示有效或补充曲妥珠单抗的药物在GEA未显示临床获益。
- 耐药主要归因于肿瘤异质性,存在低表达ERBB2的肿瘤克隆及ERBB2随时间丢失。
- 酪氨酸激酶受体共扩增、MAPK和PI3K信号通路及细胞周期调控蛋白改变可被双靶向治疗。
- NF1突变导致Ras磷酸化和激活,可联合MEK/ERK抑制与抗ERBB2治疗。
临床怎么用
- 作者认为新型ERBB2检测策略和具旁观者效应的抗体偶联药物为对抗ERBB2阳性GEA异质性提供新工具。
- 作者认为更好地理解免疫机制可 leverage 抗ERBB2治疗的免疫作用并阐明免疫治疗联合抗ERBB2治疗的疗效,如KEYNOTE-811试验近期中期阳性结果所提示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ERBB2 is the most prominent therapeutic target in gastroesophageal adenocarcinoma (GEA). For two decades, trastuzumab was the only treatment available for GEA overexpressing ERBB2. Several drugs showing evidence of efficacy over or in complement to trastuzumab in breast cancer failed to show clinical benefit in GEA. This resistance to anti-ERBB2 therapy is peculiarly recurrent in GEA and is mostly due to tumor heterogeneity with the existence of low expressing ERBB2 tumor clones and loss of ERBB2 over time. The development of new ERBB2 testing strategies and the use of antibody-drug conjugates having a bystander effect are providing new tools to fight heterogeneity in ERBB2-positive GEA. Co-amplifications of tyrosine kinase receptors, alterations in mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) signaling pathways and in proteins controlling cell cycle are well known to contribute resistance to anti-ERBB2 therapy, and they can be targeted by dual therapy. Recently described, NF1 mutations are responsible for Ras phosphorylation and activation and can also be targeted by MEK/ERK inhibition along with anti-ERBB2 therapy. Multiple lines of evidence suggest that immune mechanisms involving antibody-dependent cell-mediated cytotoxicity are preponderant over intracellular signaling in anti-ERBB2 therapy action. A better comprehension of these mechanisms could leverage immune action of anti-ERBB2 therapy and elucidate efficacy of combinations associating immunotherapy and anti-ERBB2 therapy, as suggested by the recent intermediate positive results of the KEYNOTE-811 trial.
引用
- Augustin JE, Soussan P, Bass AJ, et al. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann Oncol. 2022. PMID: 35963482. doi:10.1016/j.annonc.2022.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。